Degasperi E, Galmozzi E, Facchetti F, Farina E, D'Ambrosio R, Soffredini R, Iavarone M, Lampertico P. TLL1 variants do not predict hepatocellular carcinoma development in HCV cirrhotic patients treated with direct-acting antivirals. J Viral Hepat 2019;26:1233-6. [PMID: 31177595 DOI: 10.1111/jvh.13155][Cited by in Crossref: 5][Cited by in F6Publishing: 6][Article Influence: 1.7][Reference Citation Analysis]
2
Frías M, Rivero-juárez A, Machuca I, Camacho Á, Rivero A. The outlook for precision medicine for the treatment of chronic hepatitis C infection: challenges and opportunities. Expert Review of Precision Medicine and Drug Development 2020;5:253-63. [DOI: 10.1080/23808993.2020.1764346][Reference Citation Analysis]
Matsumoto K, Miyaaki H, Fukushima M, Sasaki R, Haraguchi M, Miuma S, Nakao K. The impact of single-nucleotide polymorphisms on liver stiffness and controlled attenuation parameter in patients treated with direct-acting antiviral drugs for hepatitis C infection. Biomed Rep 2022;16:9. [PMID: 34987793 DOI: 10.3892/br.2021.1492][Reference Citation Analysis]